Huntingtons Disease Society of America

Protect Hope for Huntington’s Disease Families
We need your voice. Recent reporting raises concerns that the FDA may be changing expectations at the end of gene therapy trials, including the trial for the Huntington's disease (HD) treatment AMT-130 being developed by uniQure. 

For patients and families who are already living with HD delays in the development and approval of therapies are more than a policy issue—they mean lost time that patients simply do not have. Please take a moment to email your member of Congress and ask them to seek answers from the FDA about these decisions and their potential impact on patients with Huntington's disease.

    Subject
    Message Body
    Remaining: 0
    Post
    Remaining: 0
    Suggested Message
    Post
    Remaining: 0
  • Hide
    • Please call this number:

      Please do not close this window. You will need to come back to this window to enter your code.
      We just sent an email to ... containing a verification code.

      If you do not see the email within the next five minutes, please ensure you entered the correct email address and check your spam/junk mail folder.
      Enter Your Info
      Your Information
      By providing your mobile number, you agree to receive periodic call to action text messages from Huntingtons Disease Society of America. Message and data rates may apply. Reply HELP for help. Reply STOP to unsubscribe. Message frequency varies. Privacy Policy  
      Home Information

      Enter Your Info